Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.


Last reviewed on RxList: 1/23/2020
Vizamyl Side Effects Center

Last reviewed on RxList 1/23/2020

What Is Vizamyl?

Vizamyl (flutemetamol F 18) Injection is a molecular imaging agent used for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.

What Are Side Effects of Vizamyl?

Common side effects of Vizamyl include:

  • flushing (warmth, redness, or tingling feeling of the skin)
  • increased blood pressure
  • headache
  • nausea, and
  • dizziness

Dosage for Vizamyl

The recommended dose for Vizamyl is 185 megabecquerels (MBq) [5 millicuries (mCi)] in a maximum dose volume of10 mL, administered as a single intravenous bolus with in 40 seconds. The maximum mass dose is 20 micro grams.

What Drugs, Substances, or Supplements Interact with Vizamyl?

Vizamyl may interact with other drugs. Tell your doctor all medications and supplements you use.

Vizamyl During Pregnancy and Breastfeeding

During pregnancy, Vizamyl should be used only if prescribed. Vizamyl should not be used during breastfeeding for 24 hours after exposure to Vizamyl. Consult your doctor before breastfeeding.

Additional Information

Our Vizamyl (flutemetamol F 18) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Dementia, Alzheimer's Disease, and Aging Brains See Slideshow
Vizamyl Professional Information


Clinical Trials Experience

Clinical trials are conducted under widely varying conditions and adverse reaction rates observed in the clinical trials of Vizamyl cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In clinical trials, 761 adults (367 men and 394 women, 91% Caucasian) with a mean age of 62 years (range 18-93 years) received Vizamyl. Most subjects (530, 70%) received a dose of 185 MBq (5 mCi).

One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.

Most adverse reactions were mild to moderate in intensity and resolved spontaneously. The most commonly reported adverse reactions (occurring in at least 1% of subjects) in Vizamyl-treated subjects are shown in Table 2.

Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)

Adverse ReactionN (percent of patients)
Flushing16 (2%)
Increased blood pressure13 (2%)
Headache10 (1%)
Nausea8 (1%)
Dizziness8 (1%)

Read the entire FDA prescribing information for Vizamyl (Flutemetamol F 18 Injection)


One of the first symptoms of Alzheimer's disease is __________________. See Answer
Related Resources for Vizamyl

© Vizamyl Patient Information is supplied by Cerner Multum, Inc. and Vizamyl Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors